Oncoguard® Liver blood test delivers seven times greater sensitivity for very early-stage hepatocellular carcinoma (HCC) versus standard of care
ALTUS study is the largest prospective trial of a blood test for liver cancer surveillance in the United States, reflecting the racial and ethnic diversity of high-risk groups MADISON, Wis. / Nov 07, 2025 / Business Wire / Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today... Read more
PMA submission targeted for Q1 2026 following positive Tigris results and ongoing FDA interactions
Company to host Corporate Update call on Wednesday, December 10, 2025 TORONTO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the third quarter and provided a corporate update.
The... Read more
Revenue of $84.1 million, growing 17% year-over-year
Raising Full Year 2025 Revenue Guidance to $325.0 million
Raising Full Year 2025 EPS Guidance to GAAP loss of approximately ($1.70) per share and Non-GAAP income of $0.30 per share
GAAP gross profit of $35.5 million, or GAAP gross margin of 42.2%; Non-GAAP gross profit of $37.2 million, or Non-GAAP gross margin of 44.3%
GAAP loss of $6.6 million, or ($0.21) per share; Non-GAAP income of $4.5 million, or $0.14 per... Read more
AUSTIN, Texas / Nov 06, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the third quarter ended September 30, 2025.
Recent Financial Highlights Generated total revenues of $592.2 million in the third quarter of 2025, compared to $439.8 million in the third quarter of 2024, an increase of 34.7%. Product revenues grew 35.3% over the same period.
Generated a gross margin... Read more
LINCOLN, Neb. & TUPELO, Miss. / Nov 06, 2025 / Business Wire / North Mississippi Health Services (NMHS), a regional leader serving 24 counties across north Mississippi and northwest Alabama, has selected NRC Health as its long-term partner in healthcare experience management and strategic improvement.
Through its eight North Mississippi Medical Center hospitals, more than 70 primary and specialty care clinics, four nursing homes, and telehealth services, NMHS has a long... Read more
SALT LAKE CITY, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will share 11 new research studies highlighting advancements in oncology and reproductive genetic testing at the National Society of Genetic Counselors (NSGC) 44th Annual Conference. Myriad’s MyRisk® Hereditary Cancer Test, FirstGene™ Multiple Prenatal Screen, Prequel® Prenatal Screen and Foresight®... Read more
Tissue-free Guardant Reveal test identifies disease progression up to 18 months earlier than standard clinical measures in patients with advanced cancer
Longitudinal circulating tumor DNA (ctDNA) monitoring across multiple timepoints provides a more accurate prediction of treatment response and disease progression than a single on-treatment analysis, reinforcing the clinical value of serial testing PALO ALTO, Calif. / Nov 06, 2025 / Business Wire / Guardant Health,... Read more
SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study in Cancers from The University of Texas MD Anderson Cancer Center showing how optical genome mapping (OGM) can address key limitations of targeted RNA-sequencing (RNA-seq) panels in detecting therapeutically-relevant gene rearrangements in acute leukemias. This peer-reviewed publication, entitled “Comparative Analysis of Targeted RNA-Seq and Optical... Read more
CareDx Extends Leadership in Kidney Transplant Molecular Testing with Launch of Unique Tissue-Based Gene Expression Assay – HistoMap Kidney SOUTH SAN FRANCISCO, Calif. / Nov 06, 2025 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today... Read more
Recorded third quarter 2025 worldwide revenue of $384.0 million, GAAP fully diluted earnings per share of $0.41, adjusted fully diluted earnings per share of $1.27 and free cash flow of $94.7 million
Separately announced upcoming retirement of CEO, departure of President and appointment of prior CEO to Executive Chairperson; Board conducting CEO search
Announced PDUFA dates for its new formulation of piflufolastat F 18 PSMA PET imaging agent; for MK-6240, its F 18... Read more
CLEVELAND, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC) (the “Company”) today announced the launch of a secondary offering (the “Offering”) of 30,000,000 shares of its common stock, par value $0.01 per share. All 30,000,000 shares are being offered for sale by certain affiliates of Warburg Pincus LLC (“Warburg Pincus”) and GTCR LLC (“GTCR”) as selling stockholders. No other entities, and no individuals, are selling shares in the... Read more
SAN DIEGO, Nov. 5, 2025 /PRNewswire/ -- The Chinese Ministry of Commerce (MOFCOM) today announced it will lift the export ban on Illumina, Inc. (NASDAQ: ILMN), which had been in place since March 4, 2025. While the ban will be lifted on November 10, Illumina remains on the Unreliable Entities List (UEL), requiring government approval for instrument purchases.
Illumina remains focused on achieving a positive resolution regarding its inclusion on the UEL and is committed... Read more
Published study adds to growing evidence that the Shield blood-based screening test boosts adherence PALO ALTO, Calif. / Nov 05, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced new real-world data published in Current Medical Research and Opinion finding that the Shield blood-based screening test demonstrates patient adherence of 95% in screening for colorectal cancer (CRC). Shield is the first and only... Read more
Total revenue of $700 million; excluding COVID-19 and Donor Screening, revenue grew mid-single digits, demonstrating solid underlying growth and momentum ―
Successful completion of debt refinancing, enhancing financial flexibility through improved terms and reduced amortization obligations ―
Full-year 2025 revenue and adjusted EBITDA guidance ranges narrowed; adjusted diluted EPS updated to reflect debt refinancing ― Third Quarter 2025 Results
(all... Read more
Announces Successful Sequencing on Prototype Proteus Unit, Development Program Remains On-Track BRANFORD, Conn. / Nov 05, 2025 / Business Wire / Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through single-molecule detection, today announced financial results for the third quarter ended September 30, 2025.
Press Release Highlights Reported revenue of $552,000 for... Read more
MENLO PARK, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2025.
Third quarter results:
Q3 2025
Q3 2024 Revenue
$38.4 million
$40.0 million Instrument revenue
$11.3 million
$16.8 million Consumable revenue
$21.3 million
$18.5 million Service and other revenue
$5.8 million
$4.7 million Revio™ systems
13
22 Vega™ sy... Read more
New multi-center study identifies 100% of clinically relevant variants in the study, including those not detected by short-read sequencing technologies, positioning HiFi as the bridge between research and clinical-grade genomics MENLO PARK, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, today announced the publication of a new preprint from the HiFi Solves EMEA Consortium, “HiFi sequencing... Read more
CHICAGO / Nov 05, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that six abstracts have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025. The meeting is taking place November 5 - 9 at the Gaylord National Convention Center in National Harbor, Maryland.
“We’re excited to join the oncology community at this year’s... Read more
Third-Quarter Revenue of $1.00 Billion
Third-Quarter GAAP Earnings per Share of $1.10 and Non-GAAP Earnings per Share of $2.43
Updates 2025 Guidance WILMINGTON, Mass. / Nov 05, 2025 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of 2025. For the quarter, revenue was $1.00 billion, a decrease of 0.5% from $1.01 billion in the third quarter of 2024.
The impact of foreign... Read more
RadNet subsidiary DeepHealth to commercialize a robust end-to-end remote-imaging offering featuring both TechLive™ remote scanning technology and Alpha RT’s MRI staffing services and training programs LOS ANGELES, Nov. 05, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) (“RadNet”), a US leader in providing high-quality, cost-effective diagnostic imaging services and digital health solutions, today announced it has acquired the assets of Alpha RT, a pioneer... Read more
RESEARCH TRIANGLE PARK, N.C. / Nov 05, 2025 / Business Wire / IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, announced the appointment of Dr. William G. Kaelin Jr. to its board of directors, effective today.
Dr. Kaelin is a Senior Physician-Scientist at Brigham and Women’s Hospital in Boston and the Sidney Farber Professor of Medicine at the Dana-Farber Cancer Institute and Harvard Medical School.... Read more
PALO ALTO, Calif. / Nov 04, 2025 / Business Wire / Guardant Health, Inc. (“Guardant Health”) (Nasdaq: GH), a leading precision oncology company, today announced the commencement of an underwritten public offering of $250.0 million of shares of Guardant Health’s common stock (the “common stock offering”). Guardant Health also intends to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of its common stock at the public... Read more
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter ended September 30, 2025.
Recent Highlights: Third quarter 2025 total combined company revenue of $46.2 million; Revenue from continuing operations of $19.6 million
Implemented restructuring plan expected to deliver over $40 million in annualized cost savings; On track to... Read more
Total Revenue of $100 Million Increased 21% Year-Over-Year
Grew Testing Services Volume to Approximately 50,300, Increase of 13% Year-Over-Year
Raised 2025 Revenue Guidance to $372 Million to $376 Million BRISBANE, Calif. / Nov 04, 2025 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company — a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions... Read more
CHICAGO / Nov 04, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended September 30, 2025. Revenue grew 84.7% year-over-year to $334.2 million in the third quarter of 2025
Gross profit reached $209.9 million in the third quarter of 2025, an improvement of 98.4% year-over-year
217,000 clinical tests delivered in the quarter,... Read more
Q3 2025 results: Net sales of $533 million (+6% at actual rates); diluted EPS $0.60 Core sales +6% CER (constant exchange rates) driven by QIAstat-Dx (+11% CER), QuantiFERON (+11% CER) and Sample technologies (+3% CER)
Solid adjusted operating income margin at 29.6%
Adjusted diluted EPS $0.61 ($0.61 CER), above outlook for at least $0.58 CER
Ongoing strong operating cash flow of $165 million Full-year 2025 outlook reaffirmed for net sales growth of about 4-5%... Read more
Parse Biosciences is a fast-growing innovator in single-cell sample preparation, with technologies used in more than 3,000 labs across over 40 countries Acquisition strengthens QIAGEN’s presence in the rapidly growing single-cell market, accelerating growth across its industry-leading Sample technologies portfolio Parse provides Evercode, a highly differentiated instrument-free platform built for analyzing millions and billions of cells for large-scale AI-driven... Read more
NMPA approval on the Sequel II CNDx system enables clinicians in China to harness PacBio HiFi sequencing for challenging conditions, with initial offering for thalassemia MENLO PARK, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, today announced that, through its long-standing partnership with Berry Genomics, the Sequel II CNDx system has received Class III Medical Device Registration... Read more
October Revenue Grew 32% MoM and on Track to hit $10 Million in Monthly Revenue by December 2025 CHARLOTTE, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (Nasdaq: PRE) (“Prenetics”), a leading health sciences company and parent of the IM8 premium health and longevity brand, today announced a record breaking month for IM8 in October, reaching approximately $108 million in annualized recurring revenue (ARR) just 11 months after its commercial... Read more
CARLSBAD, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2025, and recent corporate updates.
Three Months Ended September 30,
Nine Months Ended September 30,
2025
2024
2025
2024 (Unaudited, in thousands, except ASP data)
Rev... Read more
SOUTH SAN FRANCISCO, Calif. / Nov 04, 2025 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience and Adam Laponis, CFO of Twist, will participate in a fireside chat at the at 7th Annual Wolfe Research Healthcare Conference on Monday, November 17, 2025 at 3:20 pm Eastern Time in New York City.
The fireside chat will be webcast live and... Read more
Delivered $37.3 million total revenue in Q3 2025, representing 11% adjusted pro forma revenue growth versus Q3 2024
Generated Greenbrook clinic revenue of $21.8 million in Q3 2025, an increase of 25% on an adjusted pro forma basis versus Q3 2024
Continued cash management improvement, with cash used in operations of $0.8 million in Q3 2025
Strengthened balance sheet in Q3 2025, ending the quarter with $34.5 million of total cash, consisting of cash, cash equivalents,... Read more
Q3 2025 net revenues increased 9.1% to $311 million, or 8.0% on a constant currency basis(1), compared to Q3 2024
Q3 2025 net income of $48 million, or $0.17 per diluted share, compared to net income of $17 million or $0.06 per diluted share in Q3 2024
Q3 2025 Adjusted EBITDA(1) increased 12.2% to $164 million, or 11.2% on a constant currency basis, compared to Q3 2024
Q3 2025 Adjusted EPS(1) of $0.26, an increase of $0.09 per diluted share, compared to Adjusted... Read more
Analysis of the all-comers PROWL Registry demonstrated high procedural success and safety in a cohort reflecting the real-world complexity of patients with symptomatic limb ischemia, over 40% of whom had symptoms lasting more than two weeks before intervention with the Pounce™ Platform. EDEN PRAIRIE, Minn. / Nov 04, 2025 / Business Wire / Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry,... Read more
Highlights Sales of $800 million exceeded guidance; grew 8% as reported and 8% in constant currency
Delivered GAAP EPS of $2.50 and non-GAAP EPS of $3.40, which reflects strong, 16% growth in Adjusted Earnings Per Share that exceeded guidance
Instruments grew 6% in constant currency, led by high single-digit LC & MS growth, and TA Division returning to positive growth
Recurring revenue grew 9% in constant currency; chemistry grew double digits, with strong uptake... Read more
VANCOUVER, BC / ACCESS Newswire / November 4, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to announce that its wholly owned German subsidiary, Vektor Pharma TF GmbH, has received an "Intention to Grant" notification from the European Patent Office (EPO) for European patent application no. 23 729 446.7, covering a sublingual, orally dispersible thin-film formulation of cladribine for the treatment of multiple sclerosis... Read more
Delivered Q3 2025 revenue of $83 million
Q3 2025 non-dermatologic revenue increased by 67% over Q3 2024
Q3 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 36% over Q3 2024
Raising full-year 2025 revenue guidance to $327-335 million from $310-320 million
Announced launch of AdvanceAD-Tx™, the Company’s test designed to guide systemic treatment decision making in patients ages 12 and older with moderate-to-severe... Read more
Highlights Third quarter 2025 revenue of $205.7 million decreased by 4% year-over-year but was flat when excluding previously discussed headwinds1 of $8.1 million, consistent with management expectations.
Third quarter 2025 hereditary cancer testing revenue and volume grew 3% and 11% year-over-year, respectively.
Third quarter 2025 gross margin was 69.9%.
Third quarter 2025 GAAP net loss of $27.4 million, or $0.29 per share, while adjusted EPS was $0.00. Third quarter... Read more
Reports record revenue, raises full-year guidance, generates record cash from operations
Third quarter and recent highlights Delivered record total third quarter revenue of $851 million, an increase of 20% on a reported and core revenue basis, including Screening revenue of $666 million and Precision Oncology revenue of $184 million
Raised full-year 2025 revenue and adjusted EBITDA guidance midpoints by $78 million and $10 million, respectively
Generated record cash... Read more
Validation study data show AdvanceAD-Tx can identify patients with AD who have a ‘JAKi responder profile’ and a superior response to JAKi therapies compared to Th2-targeted therapies FRIENDSWOOD, Texas, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the launch of AdvanceAD-Tx™, a gene expression profile (GEP) test designed to guide systemic... Read more
Company forms new AI business unit, led by Chief Technology & AI Officer Christopher Thurston, to unify and advance Co-Dx's existing and future AI initiatives SALT LAKE CITY, Nov. 3, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the formation of a newly organized, artificial intelligence... Read more
Data to highlight the precision of AI-powered Heartflow Plaque Staging framework in predicting long-term cardiovascular outcomes MOUNTAIN VIEW, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will present new late-breaking data highlighting the clinical and economic value of Heartflow Plaque Analysis at the American Heart Association (AHA) Scientific... Read more
Clearance expands menu and enables high-sensitivity troponin I measurement to aid in the diagnosis of myocardial infarction SAN DIEGO, Nov. 3, 2025 /PRNewswire/ -- The U.S. Food and Drug Administration ("FDA") has granted QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a global leader of in vitro diagnostics, 510(k) clearance for the VITROS hs Troponin I Reagent Pack (the "VITROS hs Troponin I Assay"). The assay is intended for the... Read more
Achieves third quarter revenue growth of 13% as reported and 12% organic, and CAG Diagnostics recurring revenue growth of 11% as reported and 10% organic.
Strong organic revenue growth was supported by IDEXX execution and commercial performance, reflecting benefits from IDEXX's innovation, including over 1,700 IDEXX inVue Dx™ placements.
Delivers EPS of $3.40, an increase of 21% as reported and 15% on a comparable basis, including operating margin expansion of 100 basis... Read more
PROWL Registry evaluates the Pounce™ Thrombectomy Platform for the non-surgical removal of emboli and thrombi in the peripheral arterial vasculature. Updated safety and performance data from 160 patients with symptomatic infrainguinal vessels will be shared. EDEN PRAIRIE, Minn. / Nov 03, 2025 / Business Wire / Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that Dr.... Read more
Q3 2025 Revenue of $21.8 million, an increase of 20% over Q3 2024;
Q3 2025 gross profit margin of 81%, a 400-basis point improvement from Q3 2024;
Raised FY2025 Total Revenue Guidance to $84-86 million;
Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the third quarter ended September... Read more
AUSTIN, Texas / Oct 31, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and precision medicine, today announced it will expand its Fetal Focus test to cover 20 genes, marking a major advancement in single-gene noninvasive prenatal testing (sgNIPT). Building on the success of the initial Fetal Focus 5-gene test, launched in August, the new expanded panel will launch in Q4 2025.
Fetal Focus’ unique approach, using Natera’s... Read more
Revenue of $1.08 billion for Q3 2025, flat compared to Q3 2024 on both a reported and constant currency basis
GAAP operating margin of 21.0% and non-GAAP operating margin of 24.5% for Q3 2025
GAAP diluted EPS of $0.98 and non-GAAP diluted EPS of $1.34 for Q3 2025
Cash provided by operations of $284 million and free cash flow of $253 million for Q3 2025
Repurchased 1.2 million shares of our common stock for $120 million at an average price of $97.10 per share
For... Read more
SAN DIEGO / Oct 30, 2025 / Business Wire / DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2025.
Third Quarter 2025 Financial Highlights: Revenue grew 22% year-over-year to $1.209 billion on a reported basis and 20% year-over-year on an organic1 basis.
U.S. revenue grew 21% and international revenue grew 22% on a reported basis and 18% on an organic1 basis, all on a year-over-year basis.
GAAP operating income... Read more
Additional presentations to focus on liquid biopsy– MRD based detection and genomic profiling across solid tumors FORT MYERS, Fla. / Oct 30, 2025 / Business Wire / NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, will present new research at the International Society of Liquid Biopsy (ISLB) Annual Congress 2025 demonstrating high concordance between its RaDaR® ST and RaDaR® 1.0 assays for detecting... Read more
